Skip to main content
logo
IRLAB Therapeutics AB (publ) (STO:IRLAB.A)
Sweden flag Sweden · Delayed Price · Currency is SEK
1.732
-0.032 (-1.81%)
Sep 2, 2026, 5:29 PM CET

IRLAB Therapeutics AB Financials Overview

Millions SEK. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
79.3357.4694.635.6861.14207.78
Revenue Growth
4.74%-39.28%1566.57%-90.71%-70.58%69160.67%
Gross Profit
0.79-41.91-41.66-122.73-64.77126.05
Operating Income
-38.63-87.02-72.97-180.09-11252.58
Net Income
-53.84-110.01-83.13-177.84-113.4151.78
Earnings Per Share
-0.64-1.64-1.60-3.43-2.191.00
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
34.2281.8666.92111.31252.78401.9
Total Debt
24.229.9560.4227.573.986.6
Net Cash (Debt)
10.0251.916.583.74248.8395.3
Net Cash Growth
-699.06%-92.24%-66.34%-37.06%44.23%
Net Cash Per Share
0.120.770.131.614.807.64

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-67.02-55.22-65.59-164.85-142.61128.64
Capital Expenditures
---0.2-0.29-2.88-0.71
Free Cash Flow
-67.02-55.22-65.79-165.14-145.49127.93
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
0.99%-72.94%-44.03%--105.94%60.66%
Operating Margin
-48.69%-151.44%-77.11%-3171.72%-183.20%25.30%
Pretax Margin
-67.87%-191.45%-87.85%-3132.07%-185.50%24.92%
Profit Margin
-67.87%-191.45%-87.85%-3132.07%-185.50%24.92%
FCF Margin
-84.47%-96.10%-69.52%-2908.47%-237.97%61.57%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-----43.97
Forward PE
-4.43----
P/FCF Ratio
-----17.80
PS Ratio
3.312.915.8968.5132.4910.96